CREDIT: XXX
SUPPLIER DIVERSITY WATCH NOW
Enhanced drug distribution security – Drug Supply Chain Security Act( DSCSA) implementation updates
Building a proactive system The issues plaguing the US’ medical device supply chain are not isolated. They reflect a broader need for strategic investment, political cooperation and regulatory clarity.
What’ s clear is that a reactive approach to medical device supply chains is not working. The FDA and other health bodies need stronger tools – legal authority, financial support and stakeholder input – to move from last-minute crisis management to long-term planning.
Engaging stakeholders from every level of the supply chain allows early risk identification and builds trust in public health systems. Better laws are part of the answer, but so is a shift in culture – to treat resilience as a shared responsibility rather than a task delegated to regulators alone. supplychaindigital. com 165